(NASDAQ: LUNG) Pulmonx's forecast annual revenue growth rate of 20.38% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.29%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Pulmonx's revenue in 2024 is $68,675,000.On average, 2 Wall Street analysts forecast LUNG's revenue for 2024 to be $3,170,853,652, with the lowest LUNG revenue forecast at $3,166,229,169, and the highest LUNG revenue forecast at $3,175,478,134. On average, 2 Wall Street analysts forecast LUNG's revenue for 2025 to be $3,848,340,370, with the lowest LUNG revenue forecast at $3,800,554,049, and the highest LUNG revenue forecast at $3,896,126,692.
In 2026, LUNG is forecast to generate $4,634,502,433 in revenue, with the lowest revenue forecast at $4,501,933,928 and the highest revenue forecast at $4,767,070,937.